8-K
filed August 3, 2026, 5:08 PM ET
ticker OBX
CIK 0002130606
M&A
confidence high
sentiment neutral
materiality 0.85
Obsidian Therapeutics completes reverse merger with Legacy Obsidian and Galera; begins trading on Nasdaq under OBX
Gazelle Parent, Inc.
- Mergers closed Aug 3, 2026; Legacy Obsidian shareholders received 0.1383 shares of Parent per share; Legacy Galera shareholders received 0.7019 shares per share.
- Concurrent PIPE of $350M from qualified investors; post-merger ownership: Legacy Obsidian ~51.6%, PIPE investors ~47.2%, Legacy Galera ~1.2%.
- New board of six directors appointed, led by Chairperson Maria Fardis; includes CEO Madan Jagasia and other Legacy Obsidian designees.
- Galera shareholders receive CVRs for 80% of net proceeds from Legacy Product (5 years) and 95% from Supportive-Care Product Divestiture (10 years).
- KPMG appointed as independent auditor; Parent Common Stock to trade on Nasdaq under ticker OBX starting Aug 4, 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Julie Feder resigned as Director at Gazelle Parent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
J. Mel Sorensen, M.D. and Julie Feder resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with our company relating to our operations, policies or practices.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Madan Jagasia, M.D., M.S. was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Heidi Hagen was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
J. Mel Sorensen, M.D. resigned as Director at Gazelle Parent, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
J. Mel Sorensen, M.D. and Julie Feder resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with our company relating to our operations, policies or practices.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew Norkunas, M.D., M.B.A. was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Maria Fardis, Ph.D., M.B.A. was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Maria Fardis, Ph.D., M.B.A. was appointed as Chairperson of the Board at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Chairperson of the Board
Exact text from the filing
Maria Fardis, Ph.D. was appointed Chairperson of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Barrett, Ph.D. was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Ross, M.D. was appointed as Director at Gazelle Parent, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board was reconstituted as follows: Peter Barrett, Ph.D., Matthew Norkunas, M.D., M.B.A., Heidi Hagen, Madan Jagasia, M.D., M.S., Maria Fardis, Ph.D., M.B.A., and Robert Ross, M.D. (each designated by Legacy Obsidian).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.